+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immuno-oncology Clinical Trials Market - Global Forecast 2026-2032- Product Image
Immuno-oncology Clinical Trials Market - Global Forecast 2026-2032- Product Image
New

Immuno-oncology Clinical Trials Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674772
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immuno-oncology clinical trials market is undergoing a significant transformation as scientific innovation intersects with complex operational and regulatory realities. For senior decision-makers, a clear understanding of these dynamics is critical to optimizing strategic planning, resource allocation, and partnership decisions in this competitive space.

Market Snapshot: Immuno-Oncology Clinical Trials Market

The Immuno-oncology Clinical Trials Market grew from USD 7.40 billion in 2025 to USD 8.32 billion in 2026. It is expected to continue growing at a CAGR of 14.81%, reaching USD 19.47 billion by 2032.

Scope & Segmentation

  • Therapy Modalities: Categories include adoptive cell therapies (CAR-T, NK cell therapy, TCR-T), cancer vaccines (dendritic cell, DNA, peptide), checkpoint inhibitors (CTLA-4, PD-1, PD-L1), cytokine therapies (variants such as interferon alpha, interferon gamma, interleukin-2), and oncolytic viruses.
  • Trial Phases: Spans from Phase I (dose escalation, translational biomarker readouts) through Phase II and III (emphasizing efficacy endpoints and stratified enrollment) to Phase IV (real-world and post-marketing outcomes).
  • Indications: Segmentation by solid tumors (breast, lung, colorectal, melanoma) and hematological malignancies (leukemia, lymphoma, myeloma), recognizing distinct clinical and operational demands.
  • Sponsor Types: Includes biotechnology firms, pharmaceutical companies, academic institutions, and consortia, each with varied risk appetites and collaboration models.
  • Trial Designs: Covers interventional trials focusing on therapeutic evaluation and observational studies capturing real-world evidence and biomarker trends.
  • Patient Enrollment Scales: Encompasses small, medium, and large-scale trials, influencing site selection, monitoring, and statistical design.
  • Regions: Encompasses the Americas, Europe, Middle East & Africa, and Asia-Pacific—each with unique infrastructure, regulatory standards, and patient access dynamics.

Key Takeaways for Strategic Planning

  • Scientific advances are rapidly changing the investigational agent landscape, requiring new approaches to trial design and endpoint selection.
  • Increased operational complexity arises from evolving trial formats like seamless phase models and platform-based protocols, making robust data management and safety oversight essential.
  • Regulatory expectations now emphasize mechanistic evidence, standardized potency assays for cellular products, and strong post-approval evidence frameworks.
  • Collaboration between platform developers, pharmaceutical sponsors, and academic consortia is increasingly common to share risk and accelerate development timelines.
  • Segmenting by therapy type, trial phase, and region helps organizations spot operational bottlenecks and invest in areas that deliver high returns.
  • Diversified supplier networks and adaptive scenario planning are critical to managing supply chain and tariff disruptions.

Tariff Impact and Supply Chain Considerations

The introduction of tariffs in key supply markets adds complexity to procurement and manufacturing for immuno-oncology clinical trials. Cost pressures related to sourcing of reagents, consumables, and specialized equipment drive sponsors to reconsider supplier footprints and prioritize regional manufacturing hubs. These changes can influence decisions about trial site locations and cross-border resource agreements, making scenario planning and early logistics partnerships vital for safeguarding enrollment and timely product delivery.

Methodology & Data Sources

This executive analysis integrates protocol-level data from public trial registries, scientific literature reviews, regulatory documents, and insights from expert interviews. Rigorous harmonization and cross-verification of trial metadata with sponsor disclosures and regulatory filings underpin the reliability of segmentations and key findings. Limitations include variability in registry reporting and proprietary program details; however, consistent mixed-methods and peer validation strengthen the robustness of the results.

Why This Report Matters

  • Enables better resource allocation by illuminating the operational and regulatory bottlenecks unique to immuno-oncology trials.
  • Offers actionable, segment-driven insights to inform evidence generation, trial design, and partnership strategies relevant to global expansion and competitive differentiation.
  • Guides leaders in building cross-functional alignment between translational science, manufacturing, and regulatory functions—key for accelerating program advancement and de-risking investment.

Conclusion

Success in the immuno-oncology clinical trials market hinges on integrated strategies that address both the opportunities and challenges of evolving modalities, regulatory landscapes, and operational demands. Strategic alignment across scientific, operational, and regional functions positions organizations to realize long-term clinical and commercial outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Immuno-oncology Clinical Trials Market, by Therapy Type
8.1. Adoptive Cell Therapies
8.1.1. Car-T
8.1.2. Nk Cell Therapy
8.1.3. Tcr-T
8.2. Cancer Vaccines
8.2.1. Dendritic Cell Vaccines
8.2.2. Dna Vaccines
8.2.3. Peptide Vaccines
8.3. Checkpoint Inhibitors
8.3.1. Ctla-4 Inhibitors
8.3.2. Pd-1 Inhibitors
8.3.3. Pd-L1 Inhibitors
8.4. Cytokine Therapies
8.4.1. Interferon Therapies
8.4.1.1. Interferon Alpha
8.4.1.2. Interferon Gamma
8.4.2. Interleukin-2
8.5. Oncolytic Viruses
9. Immuno-oncology Clinical Trials Market, by Trial Phase
9.1. Phase I
9.2. Phase Ii
9.3. Phase Iii
9.4. Phase Iv
10. Immuno-oncology Clinical Trials Market, by Indication
10.1. Hematological Malignancies
10.1.1. Leukemia
10.1.2. Lymphoma
10.1.3. Myeloma
10.2. Solid Tumors
10.2.1. Breast Cancer
10.2.2. Colorectal Cancer
10.2.3. Lung Cancer
10.2.4. Melanoma
11. Immuno-oncology Clinical Trials Market, by Trial Type
11.1. Interventional
11.2. Observational
12. Immuno-oncology Clinical Trials Market, by Sponsor Type
12.1. Academic Institutions
12.2. Biotechnology Companies
12.3. Consortiums
12.4. Pharmaceutical Companies
13. Immuno-oncology Clinical Trials Market, by Patient Enrollment
13.1. Large Scale
13.2. Medium Scale
13.3. Small Scale
14. Immuno-oncology Clinical Trials Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Immuno-oncology Clinical Trials Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Immuno-oncology Clinical Trials Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Immuno-oncology Clinical Trials Market
18. China Immuno-oncology Clinical Trials Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Charles River Laboratory
19.6. Clinipace Company
19.7. Eli Lilly and Company
19.8. ICON PLC
19.9. IQVIA
19.10. Novo Nordisk A/S
19.11. PAREXEL International Corporation
19.12. Pfizer Inc.
19.13. PRA Health Sciences
19.14. SGS SA
19.15. Syneos Health
19.16. Wuxi AppTec Inc.
List of Figures
FIGURE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CAR-T, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TCR-T, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERLEUKIN-2, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ONCOLYTIC VIRUSES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CONSORTIUMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY LARGE SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY MEDIUM SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SMALL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 145. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 146. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 147. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 192. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 194. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 195. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 196. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 197. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 198. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 199. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 200. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 201. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 202. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 203. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 204. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 205. EUROPE IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 220. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 221. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 222. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 223. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 224. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 225. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 226. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 227. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 228. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 229. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 230. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 231. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 232. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 233. AFRICA IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 236. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 237. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 238. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 239. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 240. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 241. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 242. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 243. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 244. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 245. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 246. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 247. ASIA-PACIFIC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 248. GLOBAL IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 249. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 250. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 251. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 252. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 253. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 254. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 255. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 256. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 257. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 258. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 259. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 260. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 261. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 262. ASEAN IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 263. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 264. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 265. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 266. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 267. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 268. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 269. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 270. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 271. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 272. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 273. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 274. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 275. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR TYPE, 2018-2032 (USD MILLION)
TABLE 276. GCC IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY PATIENT ENROLLMENT, 2018-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY ADOPTIVE CELL THERAPIES, 2018-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY CYTOKINE THERAPIES, 2018-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INTERFERON THERAPIES, 2018-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY TRIAL TYPE, 2018-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION IMMUNO-ONCOLOGY CLINICAL TRIALS MARKET SIZE, BY SPONSOR T

Companies Mentioned

The key companies profiled in this Immuno-oncology Clinical Trials market report include:
  • Charles River Laboratory
  • Clinipace Company
  • Eli Lilly and Company
  • ICON PLC
  • IQVIA
  • Novo Nordisk A/S
  • PAREXEL International Corporation
  • Pfizer Inc.
  • PRA Health Sciences
  • SGS SA
  • Syneos Health
  • Wuxi AppTec Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.32 Billion
Forecasted Market Value ( USD ) by 2032 $ 19.47 Billion
Compound Annual Growth Rate14.8%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Immuno-Oncology Market - Global Forecast 2026-2032 - Product Image

Immuno-Oncology Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Immuno-Oncology Service Market - Global Forecast 2026-2032 - Product Image

Immuno-Oncology Service Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030 - Product Image

Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024-2030

  • Report
  • Global
From

About the Immuno Oncology Clinical Trials Market

Immuno Oncology (IO) is a rapidly growing field of oncology drug development that focuses on harnessing the body's own immune system to fight cancer. IO drugs are designed to target and block specific pathways that cancer cells use to evade the immune system. These drugs can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. IO clinical trials are designed to evaluate the safety and efficacy of these drugs in treating various types of cancer. IO clinical trials are conducted in phases, with each phase designed to assess different aspects of the drug's safety and efficacy. Phase I trials are typically conducted in small groups of patients to assess the drug's safety and tolerability. Phase II trials are larger and are designed to assess the drug's efficacy in treating a specific type of cancer. Phase III trials are the largest and are designed to compare the drug's efficacy to existing treatments. Some of the major companies in the IO clinical trials market include Merck, Bristol-Myers Squibb, AstraZeneca, Roche, and Novartis. These companies are actively involved in the development and testing of IO drugs for the treatment of various types of cancer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.